Tag: Immunovaccine

May 3, 2018

Notes from the Floor: Bloom Burton & Co., Day 2

The Bloom Burton & Co. Healthcare Investor Conference was held from May 2 to 3 in Toronto — here’s what...
April 24, 2018

Immunovaccine and Incyte Expand Collaboration

Collaborations are allow companies sharing scientific integrity to build their pipelines without giving away the rights to their products.
April 24, 2018

Immunovaccine and Incyte Expand Clinical Collaboration Evaluating Combination Immunotherapies in Advanced Recurrent Ovarian Cancer

Immunovaccine (TSX:IMV) (OTCQX:IMMVF), a clinical stage immuno-oncology company, today announced that it has entered into an agreement with Incyte Corporation...
April 16, 2018

New Preclinical Studies Reinforce the Potential for Heightened Anti-Cancer Activity of Combination Therapies Based on Immunovaccine’s Proprietary Delivery Platform

Immunovaccine (TSX:IMV) (OTCQX:IMMVF), a clinical stage immuno-oncology company, today announced that it presented new research on its T-cell activating platform...
March 28, 2018

Immunovaccine Announces Initiation of Patient Dosing in Investigator-Sponsored Phase 2 Clinical Trial

Immunovaccine (TSX:IMV) a clinical stage immuno-oncology company, today announced that the first patient has been treated in a Phase 2...
March 21, 2018

Immunovaccine Announces Year-End 2017 Financial Results

Immunovaccine (TSX:IMV) a clinical stage immuno-oncology corporation, today released its financial and operational results for the fiscal year ended December...
January 31, 2018

Published Study Demonstrates the Association Between Immunovaccine’s Proprietary Immune-targeted Delivery Technology

Immunovaccine (TSX:IMV) a clinical stage immuno-oncology company, announced the publication of a preclinical study using magnetic resource imaging (MRI) to...